Compare FBDT & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBDT | JSPR |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.2M | 26.3M |
| IPO Year | 2026 | 2019 |
| Metric | FBDT | JSPR |
|---|---|---|
| Price | $0.89 | $0.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 6.5M | 448.0K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.22 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $0.32 |
| 52 Week High | $1.25 | $2.69 |
| Indicator | FBDT | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 60.70 | 41.43 |
| Support Level | $0.71 | $0.55 |
| Resistance Level | $1.25 | $1.01 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 44.06 | 28.89 |
First Breach Inc is an American defense technologies company focused on manufacturing match-grade ammunition components, finished ammunition, and developing unmanned aerial systems for commercial, law enforcement, and military markets. Its ammunition operations include the in-house production of brass cups, casings, projectiles, lead cores, lead wire, and completed ammunition. The company is also developing U.S.-made unmanned aerial systems incorporating robotics, intelligence, surveillance and reconnaissance (ISR), sensor, and precision manufacturing technologies for defense, homeland security, law enforcement, and commercial applications.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.